Sign In
Buy ORIC
$12.06
-0.190 (-1.55%)
At Close: Nov 17, 2025
ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
04:10pm, Thursday, 13'th Nov 2025
Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety
Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and deep ctDNA reductions
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 07'th Nov 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address m
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
04:30pm, Tuesday, 04'th Nov 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
10:25am, Wednesday, 22'nd Oct 2025
ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Sep 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address
ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript
07:37pm, Wednesday, 03'rd Sep 2025
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC ) Pharmaceuticals, Inc. Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants Jacob Chacko - President, CEO & Director D
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 27'th Aug 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
04:05pm, Monday, 18'th Aug 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates
04:05pm, Tuesday, 12'th Aug 2025
Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cas
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 01'st Aug 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address m
Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?
10:56am, Tuesday, 15'th Jul 2025
From a technical perspective, Oric Pharmaceuticals, Inc. (ORIC) is looking like an interesting pick, as it just reached a key level of support. ORIC's 50-day simple moving average crossed above its 20
Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?
01:01pm, Friday, 11'th Jul 2025
Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.
